scanX
J B Chemicals and Pharmaceuticals

J B Chemicals and Pharmaceuticals

1,771.30
+14.70
(0.84%)
hide
Key Fundamentals
Add Ratio
Market Cap
27,737.89 Cr
EPS
42.45
PE Ratio
38.02
Dividend Yield
0.88 %
Industry
Healthcare
52 Week High
1,952.00
52 Week Low
1,385.75
PB Ratio
7.18
Debt to Equity
0.06
Sector
Pharmaceuticals
Analyst Rating and Forecast
- By Refinitiv from11 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+72.73 %
+72.73 %
Hold
Hold+27.27 %
+27.27 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
J.B. Chemicals Allots 21,056 Equity Shares Under Employee Stock Option Scheme2 days ago
J.B. Chemicals & Pharmaceuticals Limited allotted 21,056 fully paid-up equity shares of Re. 1 each to an employee under its Employee Stock Option Scheme, 2021, realizing Rs. 78,43,360. The company's issued and paid-up capital increased from 15,66,27,400 equity shares to 15,66,48,456 equity shares of Re. 1 each.
neutral
Torrent Pharmaceuticals Launches Open Offer for J.B. Chemicals at INR 1,639.18 Per Share8 days ago
Torrent Pharmaceuticals Limited has initiated an open offer to acquire up to 4,17,45,264 equity shares of J.B. Chemicals & Pharmaceuticals Limited, representing 26% of expanded share capital at INR 1,639.18 per share. The offer aggregates to INR 6,842.8 crore assuming full acceptance, with the offer opening advertisement published on November 17, 2025.
positive
J.B. Chemicals Reports 16% Revenue Growth in Q2 FY26, Torrent Acquisition Gets CCI ApprovalNov 11, 2025
J.B. Chemicals & Pharmaceuticals reported consolidated revenue of ₹1,040 crores for the quarter ended September 30, 2025, compared to ₹896 crores in the same period last year. Net profit increased to ₹208 crores from ₹175 crores year-over-year. For the half-year period, consolidated revenue grew to ₹2,008 crores from ₹1,836 crores, with net profit rising to ₹410 crores from ₹351 crores. The Competition Commission of India approved Torrent Pharmaceuticals' acquisition of the company on October 21, 2025, subject to voluntary modifications. Under the proposed merger scheme, Torrent will issue 51 equity shares for every 100 shares of J.B. Chemicals held by shareholders. The company allotted 9.19 lakh equity shares during the half-year under its ESOS scheme, increasing paid-up capital to ₹15.66 crores.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,776.80
#1 4,26,313.84
40.68
#1 54,729.00
9.71
#1 10,980
2.89
70.04
Divis Laboratories
6,412.00
1,70,218.45
69.05
9,712.00
18.67
2,191
35.10
45.55
Torrent Pharmaceuticals
3,745.20
1,26,754.59
58.80
11,539.40
6.99
1,911
30.46
56.93
Cipla
1,507.50
1,21,768.93
22.73
28,409.50
7.12
5,291
3.71
42.68
Dr Reddys Laboratories
1,236.10
1,03,166.61
#1 18.15
33,741.20
16.73
5,725
-0.38
48.69
Zydus Life Science
928.50
93,428.83
18.56
23,511.00
18.55
4,615
34.60
34.91
Lupin
2,042.30
93,282.98
21.34
22,909.50
13.74
3,306
#1 72.75
59.01
Mankind Pharma
2,241.90
92,536.33
52.05
12,744.20
#1 20.90
2,007
-21.05
35.90
Aurobindo Pharma
1,208.00
70,160.84
20.70
32,345.60
9.43
3,484
3.81
61.70
Alkem Laboratories
5,701.00
68,164.01
28.29
13,458.30
3.70
2,216
10.98
57.85

Automatic Screeners on ScanX

Community
Resistance 1 Breached
Growth Rate
Revenue Growth
12.35 %
Net Income Growth
19.36 %
Cash Flow Change
12.72 %
ROE
1.64 %
ROCE
-3.02 %
EBITDA Margin (Avg.)
1.96 %

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
408
444
398
435
459
475
445
447
545
452
604
554
619
613
605
627
786
811
796
767
902
889
852
878
1,010
1,011
972
964
1,109
1,100
Expenses
326
354
304
353
350
356
339
362
367
334
377
405
442
466
473
500
612
625
618
599
664
638
621
664
724
730
709
723
793
775
EBITDA
82
90
94
81
109
119
106
85
178
119
227
149
177
146
133
127
174
186
178
168
238
251
231
215
286
281
263
241
315
325
Operating Profit %
20 %
19 %
20 %
16 %
22 %
22 %
21 %
18 %
30 %
25 %
31 %
23 %
27 %
21 %
21 %
20 %
22 %
23 %
22 %
21 %
26 %
28 %
26 %
23 %
28 %
27 %
26 %
24 %
28 %
29 %
Depreciation
15
15
15
12
16
16
17
17
17
18
17
17
18
16
17
22
26
28
28
32
31
32
34
41
41
42
42
46
43
44
Interest
1
1
1
1
1
1
1
1
4
2
1
1
1
1
1
2
6
8
8
14
12
10
13
9
6
2
3
2
1
1
Profit Before Tax
66
75
78
68
92
102
88
67
157
99
209
132
158
129
114
103
142
150
141
123
194
209
184
165
240
237
218
193
272
279
Tax
21
23
28
22
30
8
22
17
38
25
54
31
39
32
30
18
37
39
35
35
52
58
50
38
63
62
56
47
69
71
Net Profit
46
52
50
47
62
94
66
50
120
74
154
101
119
98
84
85
105
111
106
88
142
151
134
126
177
175
163
146
202
208
EPS in ₹
5.46
6.14
6.07
5.68
7.73
11.67
8.26
6.30
15.45
9.55
19.94
13.02
15.38
12.65
10.85
10.98
13.59
14.37
13.72
11.33
9.20
9.72
8.62
8.22
11.39
11.24
10.46
9.36
12.99
13.29
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
1,487
1,648
1,674
1,765
1,792
1,821
2,238
2,607
3,554
3,994
4,274
Fixed Assets
329
440
679
640
621
651
634
1,277
1,901
2,004
1,968
Current Assets
901
816
795
1,047
1,051
1,073
1,553
1,253
1,528
1,853
1,923
Capital Work in Progress
55
135
4
17
15
16
26
19
55
76
63
Investments
367
479
411
434
457
403
678
13
206
388
345
Other Assets
737
594
580
674
699
750
901
1,299
1,392
1,525
1,897
Total Liabilities
1,487
1,648
1,674
1,765
1,792
1,821
2,238
2,607
3,554
3,994
4,274
Current Liabilities
460
431
281
275
244
313
345
384
554
868
632
Non Current Liabilities
33
31
27
46
65
69
79
85
519
203
208
Total Equity
995
1,186
1,366
1,444
1,483
1,438
1,813
2,139
2,480
2,923
3,433
Reserve & Surplus
978
1,167
1,347
1,425
1,464
1,420
1,794
2,119
2,465
2,908
3,418
Share Capital
17
17
17
17
16
16
16
16
16
16
16
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
13
15
-28
43
11
-6
-3
34
20
11
27
Investing Activities
-112
-26
-45
-21
-28
24
-231
2
-962
-404
-296
Operating Activities
127
140
201
123
194
276
315
170
626
801
903
Financing Activities
-1
-100
-184
-60
-156
-306
-87
-138
357
-386
-580
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
55.91 %
55.91 %
55.91 %
54.00 %
54.00 %
54.00 %
53.96 %
53.95 %
53.93 %
53.91 %
53.86 %
53.83 %
53.78 %
53.77 %
53.74 %
53.66 %
47.84 %
47.73 %
47.56 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
10.05 %
0.00 %
11.06 %
12.17 %
13.63 %
14.64 %
18.30 %
17.77 %
15.30 %
DIIs
12.41 %
12.32 %
14.76 %
16.03 %
16.67 %
17.52 %
18.08 %
18.54 %
19.08 %
18.65 %
18.58 %
17.97 %
18.38 %
17.62 %
16.81 %
16.41 %
18.72 %
19.63 %
22.83 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.00 %
0.01 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
20.50 %
19.69 %
17.64 %
18.38 %
17.87 %
17.37 %
16.94 %
16.70 %
15.98 %
15.66 %
15.34 %
15.17 %
14.69 %
14.38 %
13.87 %
13.42 %
13.28 %
13.04 %
12.47 %
Others
11.18 %
12.08 %
11.70 %
11.58 %
11.47 %
11.10 %
11.02 %
10.81 %
11.00 %
11.79 %
2.17 %
13.03 %
2.09 %
2.05 %
1.94 %
1.87 %
1.86 %
1.83 %
1.84 %
No of Share Holders
0
65,715
70,740
71,788
64,861
61,314
60,268
58,629
56,633
55,965
60,817
63,230
63,892
66,953
62,743
62,081
63,948
70,064
71,957

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 5 1 2 5 11 16.5 16.5 17.75 12.25 15.5
Dividend Yield (%) 2.89 0.64 1.1 1.96 1.75 2.1 1.67 1.08 0.75 0.88

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
22 Feb 2021 DIVIDEND Dividend
₹ 8.50 /share
 18 Feb 2021 520.90 555.25
02 Sept 2021 DIVIDEND Dividend
₹ 8.00 /share
 01 Sept 2021 770.03 850.15
24 Feb 2022 DIVIDEND Dividend
₹ 8.50 /share
 23 Feb 2022 852.88 804.93
17 Aug 2022 DIVIDEND Dividend
₹ 8.00 /share
 12 Aug 2022 785.18 931.68
18 Feb 2023 DIVIDEND Dividend
₹ 8.50 /share
 17 Feb 2023 1,008.50 982.73
17 Aug 2023 DIVIDEND Dividend
₹ 9.25 /share
 17 Aug 2023 976.00 1,315.08
24 May 2023 SPLIT Split
1:2
 18 Sept 2023 976.00 976.00
16 Feb 2024 DIVIDEND Dividend
₹ 5.50 /share
 16 Feb 2024 1,708.40 1,664.30
14 Aug 2024 DIVIDEND Dividend
₹ 6.75 /share
 14 Aug 2024 1,832.55 1,941.60
21 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 21 Aug 2024 1,788.80 1,942.60
06 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 06 Nov 2024 1,895.75 1,852.00
04 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 04 Feb 2025 1,805.05 1,714.10
08 Feb 2025 DIVIDEND Dividend
₹ 8.50 /share
 07 Feb 2025 1,714.10 1,673.75
14 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 14 May 2025 1,658.70 1,579.85
30 Jul 2025 DIVIDEND Dividend
₹ 7.00 /share
 30 Jul 2025 1,579.85 1,802.60
30 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 30 Jul 2025 1,651.85 1,802.60
06 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 06 Aug 2025 1,612.55 1,692.45
11 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 11 Nov 2025 1,708.80 1,813.40

Announcements

Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS2 days ago
Updates on Open Offer8 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 14, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSNov 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 12, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 11, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 11, 2025
Board Meeting Outcome for Outcome Of Board MeetingNov 11, 2025
Letter of OfferNov 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 31, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 31, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 31, 2025
4Th Sustainability (ESG) ReportOct 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 24, 2025
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter And Half Year Ended On September 30 2025.Oct 24, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Closure of Trading WindowSep 30, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 08, 2025
Updates on Open OfferSep 04, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 01, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateAug 31, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 14, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 11, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 06, 2025
Announcement under Regulation 30 (LODR)-Change in Registered Office AddressAug 06, 2025
Appointment Of Secretarial AuditorsAug 06, 2025
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sAug 06, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateAug 06, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateAug 06, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateAug 06, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateAug 06, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 31, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 31, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 30, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 30, 2025
Board Meeting Outcome for 1Unaudited Standalone And Consolidated Financial Results For The Quarter Ended On June 30 2025 Accompanied By Limited Review Report.Jul 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 23, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 22, 2025
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter Ended On June 30 2025Jul 21, 2025
Letter To Shareholders - Integrated Annual ReportJul 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 17, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 12, 2025
Draft Letter of OfferJul 12, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 11, 2025
Intimation Of Record DateJul 11, 2025
Reg. 34 (1) Annual Report.Jul 11, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Invesco India Smallcap Fund Direct - Growth
0.00%
-438823
-0.93%
-0.98%
Canara Robeco Equity Hybrid Fund Direct-Growth
0.44%
301100
0.44%
0.44%
Tata India Pharma & Healthcare Fund Direct-Growth
3.22%
253705
3.22%
3.22%
Aditya Birla Sun Life Small Cap Fund Direct-Growth
0.00%
-200000
-0.70%
-0.71%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
1.51%
178725
0.41%
0.39%
Franklin India Large & Mid Cap Fund Direct-Growth
3.00%
83669
0.22%
0.22%
Union Midcap Fund Direct - Growth
0.00%
-70255
-0.77%
-0.80%
Sundaram Multi Cap Fund Direct-Growth
0.95%
-60850
-0.42%
-0.44%
ITI Small Cap Fund Direct-Growth
0.89%
-22138
-0.21%
-0.38%
Mirae Asset Multi Asset Allocation Fund Direct - Growth
0.29%
15000
0.09%
0.07%
Axis Business Cycles Fund Direct-Growth
0.00%
-10080
-0.08%
-0.08%
Axis Equity Savings Fund Direct-Growth
1.22%
10000
0.18%
0.17%
Kotak MNC Fund Direct-Growth
2.74%
-10000
-0.16%
-0.18%
LIC MF Healthcare Fund Direct - Growth
0.00%
-9736
-1.95%
-1.90%
Bandhan Balanced Advantage Fund Direct-Growth
0.05%
6700
0.05%
0.05%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
6.48%
5425
-0.45%
-0.32%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.66%
1532
-0.04%
-0.08%
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
0.67%
1411
-0.04%
-0.07%
Axis Nifty Smallcap 50 Index Fund Direct-Growth
1.78%
-809
-0.13%
1.78%
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
0.66%
479
-0.03%
-0.08%
DSP Nifty Smallcap250 Quality 50 Index Fund Direct - Growth
2.41%
368
-0.12%
-0.10%
WhiteOak Capital Equity Savings Fund Direct - Growth
0.26%
279
-0.04%
-0.08%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.66%
244
-0.04%
-0.08%
Motilal Oswal Nifty 500 Index Fund Direct - Growth
0.07%
181
0.00%
-0.01%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.66%
134
-0.04%
-0.08%

Technical Indicators

RSI(14)
Neutral
55.62
ATR(14)
Less Volatile
34.47
STOCH(9,6)
Neutral
37.48
STOCH RSI(14)
Oversold
17.76
MACD(12,26)
Bearish
-4.42
ADX(14)
Strong Trend
25.95
UO(9)
Bearish
47.78
ROC(12)
Uptrend And Accelerating
4.02
WillR(14)
Neutral
-43.02
Bearish
4
Neutral
2
Bullish
3

About J B Chemicals and Pharmaceuticals

J.B. Chemicals & Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1976. It manufactures and markets a range of pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. The company specializes in gastroenterology, hypertension, and dermatology, with additional focus on nephrology, respiratory, virology, diabetes, and nicotine replacement therapy. Key brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. The company has manufacturing facilities in various locations in India and maintains a direct presence in Russia and South Africa, with distributor relationships in the US and other international markets. In 2020, Tau Investment Holdings Pte. Ltd., an affiliate of KKR, acquired a controlling stake in the company. J.B. Chemicals & Pharmaceuticals continues to expand its product portfolio through new launches and acquisitions in various therapeutic segments.
Website
https://www.jbpharma.com
Chairperson NameArun Duggal
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104